东亚药业(605177) - 2021 Q3 - 季度财报

Financial Performance - The company's operating revenue for Q3 2021 was ¥127,342,902.73, a decrease of 25.38% compared to the same period last year[6] - The net profit attributable to shareholders was a loss of ¥4,765,169.82, representing a decline of 122.03% year-on-year[6] - The net profit attributable to shareholders after deducting non-recurring gains and losses was a loss of ¥8,721,676.79, down 162.32% from the previous year[6] - Basic earnings per share for the current period were -¥0.04, a decrease of 116.00% year-on-year[7] - Total operating revenue for the first three quarters of 2021 was CNY 472,400,675.53, a decrease of 30.2% compared to CNY 677,407,579.12 in the same period of 2020[23] - Net profit for the first three quarters of 2021 was CNY 53,352,757.42, a decline of 50.5% compared to CNY 107,696,472.42 in the same period of 2020[25] - Total comprehensive income for the third quarter of 2021 was CNY 53,352,757.42, a decrease from CNY 107,696,472.42 in the same period of 2020[26] - Basic and diluted earnings per share for Q3 2021 were CNY 0.47, down from CNY 1.26 in Q3 2020[26] Cash Flow and Assets - The cash flow from operating activities showed a net outflow of ¥33,632,042.24, a decrease of 137.66% compared to the previous year[7] - Cash inflow from investment activities totaled CNY 209,966,779.41, while cash outflow was CNY 552,299,449.52, resulting in a net cash flow from investment activities of negative CNY 342,332,670.11[28] - Cash flow from financing activities was negative CNY 48,374,786.01 in the first three quarters of 2021, compared to a positive cash flow of CNY 1,340,091.44 in the same period of 2020[28] - The ending cash and cash equivalents balance as of September 30, 2021, was CNY 534,963,587.90, down from CNY 195,350,274.87 at the end of Q3 2020[28] - As of September 30, 2021, the company's cash and cash equivalents amounted to ¥546,741,587.90, a decrease from ¥989,381,857.35 at the end of 2020[19] - The total current assets decreased to ¥1,194,196,449.49 from ¥1,384,299,362.48 in the previous year[19] - The company's total assets increased to CNY 2,223,403,331.62, up from CNY 2,081,356,662.72 at the end of the previous year[21] Shareholder Information - The total number of ordinary shareholders at the end of the reporting period was 13,311[13] - The company’s major shareholders include Chi Zhengming and Chi Cheng, holding 41.48% and 6.85% of shares respectively, indicating strong family control[15] - The company has not disclosed any information regarding the participation of shareholders in margin trading or securities lending[15] Investments and Projects - The company plans to invest a total of ¥78,990,000 in various projects, including a key intermediate production project and a research center construction project[17] - The company has approved a change in the fundraising allocation for two sub-projects, totaling ¥22,870,000, to enhance production capabilities[18] - The total investment for the annual production of key intermediates is projected at ¥13,690,000 for the 7-ACCA and ¥47,676,000 for the raw material upgrade project[17] - The company has initiated trial production for the 7-ANCA60 tons technology project as of August 9, 2021[17] Operational Challenges - The company experienced a 30.26% decline in revenue year-to-date due to reduced market demand and production line upgrades[11] - The gross profit margin of major products decreased due to rising raw material prices, impacting net profit significantly[11] - The company reported a significant increase in accounts receivable, which rose to ¥63,746,173.64 from ¥97,784,171.07[19] - Research and development expenses for the first three quarters of 2021 were CNY 26,714,958.95, a decrease of 10.4% from CNY 29,926,293.94 in the same period of 2020[24] Miscellaneous - The company reported non-recurring gains of ¥1,124,115.88 from government subsidies during the reporting period[9] - The company did not report any net profit from the merged entity prior to the merger in the current or previous periods[26] - The company has not disclosed any new product launches or technological advancements in this report[22] - There are no mentions of market expansion or mergers and acquisitions in the current report[22]